Loading
Life sciences · Journal article
Frontiers in Endocrinology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Discontinuation of incretin-based pharmacotherapy is frequent and is associated with weight regain and metabolic relapse, including deterioration in cardiometabolic risk factors. New strategies are needed to preserve metabolic stability and body weight after treatment withdrawal. Whether continuous glucose monitoring (CGM) can facilitate early detection of metabolic relapse or support long-term weight maintenance after discontinuation remains unknown. This narrative review examines the indirect evidence supporting CGM use after discontinuation of incretin-based obesity pharmacotherapy, focusing primarily on adults with obesity without established diabetes, including those with normoglycemia or prediabetes. CGM can characterize postprandial glucose responses and glycemic variability under free-living conditions while also offering real-time behavioral feedback. However, no prospective studies have established whether CGM-derived metrics precede or predict weight regain, nor whether CGM-guided interventions improve long-term weight-maintenance outcomes in this setting. Moreover, validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have yet to be defined. We outline a hypothesis-generating three-phase monitoring framework for the prospective evaluation of CGM alongside body weight, appetite, dietary intake, and physical activity during the post-discontinuation transition period. If validated, unfavorable CGM trends could support earlier individualized behavioral or pharmacological intervention, before clinically meaningful weight regain or metabolic relapse occurs. Potential benefits must be balanced against costs, skin reactions, anxiety, and unnecessary dietary restrictions arising from overinterpreting unvalidated signals. CGM-guided post-pharmacotherapy care, therefore, remains investigational and requires prospective validation.